The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines.
Schirizzi A, Contino M, Carrieri L, Riganti C, De Leonardis G, Scavo MP, Perrone MG, Miciaccia M, Kopecka J, Refolo MG, Lotesoriere C, Depalo N, Rizzi F, Giannelli G, Messa C, D'Alessandro R.
Schirizzi A, et al. Among authors: messa c.
Front Oncol. 2023 Feb 16;13:1129832. doi: 10.3389/fonc.2023.1129832. eCollection 2023.
Front Oncol. 2023.
PMID: 36874116
Free PMC article.